What is the indication for Sublocade (extended‑release buprenorphine) and what are its dosing schedule, including initial and maintenance doses, as well as the recommended non‑pharmacologic treatment plan to accompany it?

Sublocade: Indication, Dosing, and Treatment Plan

Sublocade (extended-release buprenorphine) is FDA-approved for treating moderate to severe opioid use disorder and must be administered as part of a comprehensive treatment program that includes counseling and psychosocial support 1.

What Sublocade Is Used For

Sublocade is specifically indicated for patients with moderate to severe opioid use disorder who have either:

• Initiated treatment with a single dose of transmucosal buprenorphine, OR
• Are already being treated with buprenorphine 1

This monthly injectable formulation addresses the challenges of daily sublingual dosing, reducing risks of misuse, diversion, and treatment dropout 2.

Dosing Schedule

Initial Requirements

Before the first Sublocade injection, patients not currently on buprenorphine must receive an initial dose (e.g., 4 mg) of transmucosal buprenorphine 1. This verifies tolerance and prevents precipitated withdrawal 1.

Standard Dosing Regimen

The FDA-approved dosing follows this algorithm 1:

Initial Phase:

• First injection: 300 mg subcutaneously
• Second injection: 300 mg (may be given as early as 1 week after first injection, but typically monthly)

Maintenance Phase:

• Standard maintenance: 100 mg monthly (starting with third injection)
• Higher maintenance: 300 mg monthly may be considered when benefits outweigh risks

Dosing Considerations for High-Risk Populations

Recent evidence suggests that patients with heavy fentanyl use (daily use or ≥14 times/week) may benefit more from 300 mg monthly maintenance rather than 100 mg 3. In this high-risk population, the 300 mg dose showed significantly better response rates (11-15% absolute improvement in abstinence) 3.

Administration Details

• Route: Subcutaneous injection ONLY (never intravenous—serious harm or death can result) 1
• Sites: Abdomen, thigh, buttock, or back of upper arm 1
• Rotation: Injection sites must be rotated between doses 1
• Provider-administered only: This is not a take-home medication 1

Post-Injection Monitoring

Patients must be monitored in the healthcare setting after each injection to assess for worsening withdrawal or sedation; symptoms should be stable or improving before discharge 1. This is particularly critical for the first injection.

The Complete Treatment Plan

Psychosocial Component (Non-Negotiable)

The FDA label explicitly states that Sublocade must be used as part of a complete treatment program including counseling and psychosocial support 1. This is not optional—medication alone is insufficient for optimal outcomes in opioid use disorder.

Overdose Prevention

Strongly consider prescribing naloxone (or nalmefene) at initiation and renewal of Sublocade 1. Despite being on treatment, patients remain at risk for relapse and overdose, particularly during early treatment or if they discontinue.

Ongoing Monitoring

• Examine injection sites at each visit for infection or tampering 1
• Monitor liver function tests before and during treatment 1
• Assess for several months after discontinuation, as buprenorphine levels persist and withdrawal may be delayed 1

Critical Safety Considerations

REMS Program Requirement

Sublocade is only available through a restricted REMS program—healthcare settings and pharmacies must be certified to order and dispense it 1. This ensures proper administration and monitoring.

Key Warnings

• Respiratory depression risk: Particularly with concurrent benzodiazepines or CNS depressants 1
• Injection site reactions: More common with 300 mg dose (9.2% higher incidence than 100 mg), though mostly mild-to-moderate 3
• Hepatic impairment: Not recommended in moderate-to-severe hepatic impairment 1
• Neonatal withdrawal: Expected with prolonged use during pregnancy 1

Managing Acute Pain in Patients on Sublocade

If patients require opioid analgesia while on Sublocade, treat with non-opioid analgesics whenever possible; if opioids are needed, higher doses may be required due to buprenorphine's high receptor affinity, and close monitoring is essential 1. The older guidelines 4 discuss various strategies for sublingual buprenorphine, but these are less directly applicable to the long-acting depot formulation.

Treatment Retention and Efficacy

Long-term data demonstrates that after 12 months of treatment, 61-76% of patients maintained abstinence, with 50% retention rates 5. Notably, adverse events—including injection site reactions—decreased in the second 6 months compared to the first 6 months of treatment 5.

Common Pitfalls to Avoid

1. Never administer intravenously—this can cause serious harm or death 1
2. Don't skip the transmucosal test dose in buprenorphine-naive patients—this prevents precipitated withdrawal 1
3. Don't release patients immediately post-injection—monitor until stable 1
4. Don't forget psychosocial support—medication alone is inadequate 1
5. Don't assume 100 mg maintenance is sufficient for everyone—heavy fentanyl users may need 300 mg 3